CGChenchen Guo

Chenchen Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chenchen Guo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Weighted gene co-expression network analysis combined with machine learning validation to identify key hub biomarkers in colorectal cancer

    by Chenchen Guo, Bin Xie, Quanguo Liu

    Colorectal cancer (CRC) is one of the most common malignancies worldwide; however, the potentially possible molecular biological mechanism of CRC is still not completely comprehended. This study aimed to confirm candidate key hub genes involved in the growth and development of CRC and their connection with immune infiltration as well as the related pathways. Gene expression data were selected from the GEO dataset. Hub genes for CRC were identified on the basis of differential expression analysis, weighted gene co-expression network analysis (WGCNA), and LASSO regression. Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and Gene Set Enrichment Analysis (GSEA) were applied to reveal possible functions of the differential genes. Single-sample GSEA (ssGSEA) was implemented to identify the relationship between immune cells infiltration and hub genes. Two hundred and sixty-two differentially expressed genes (DEGs) were identified. Three modules were acquired based on WGCNA, and the blue module presented the highest relevance with CRC. Ten hub genes (AQP8, B3GALT5, CDH3, CEMIP, CPM, FOXQ1, PLAC8, SCNN1B, SPINK5, and SST) were acquired with LASSO analysis as underlying biomarkers for CRC. Compared with normal tissues, CRC tissues presented significantly higher numbers of CD4 T cells, CD8 T cells, B cells, natural regulatory T (Treg) cells, and monocytes. The functional enrichment analyses demonstrated that hub genes were primarily enriched in metabolic process, inflammatory-related, and immune-related response. Ten hub genes were identified to be involved in the occurrence and development of CRC and may be deemed as novel biomarkers for clinical diagnosis and treatment.


  • Prophylactic transanal drainage tube placement for preventing anastomotic leakage after anterior resection for rectal cancer: A meta‐analysis

    by Chenchen Guo, Zhiwen Fu, Xin Qing, Mengen Deng

    Aim: The aim was to evaluate the efficacy of transanal drainage tube (TDT) placement for preventing anastomotic leakage after low anterior resection for rectal cancer.Method: PubMed, the Cochrane Central Register of Controlled Trials, Embase and ClinicalTrials.gov databases were searched up to October 2021. Studies comparing outcomes following low anterior resection with or without TDT were included. The primary outcomes measured were anastomotic leakage rate, reoperation rate and anastomotic bleed rate.Results: Three randomized controlled trials (RCTs) and 16 observational studies (prospective or retrospective) involving 4560 patients satisfied the basic inclusion criteria. In RCTs, a TDT was associated with no statistically significant differences in anastomotic leakage (OR = 0.67, 95% CI 0.42–1.05, P = 0.08), reduction in reoperation (OR = 0.11, 95% CI 0.03–0.51, P = 0.004) and increased anastomotic bleeding rate (OR = 2.36, 95% CI 1.11–5.01, P = 0.03). In observational studies, a TDT was associated with significant reduction in anastomotic leak (OR = 0.44, 95% CI 0.30–0.64, P < 0.0001) and reoperation (OR = 0.47, 95% CI 0.33–0.69, P < 0.0001), with no statistically significant differences in anastomotic bleeding (OR = 1.30, 95% CI 0.20–8.30, P = 0.78).Conclusion: In RCTs, a TDT for rectal cancer was correlated with no detectable differences in anastomotic leakage and with an increased risk of anastomotic bleeding. In observational studies, a TDT was correlated with reduction in anastomotic leakage and no detectable differences in anastomotic bleeding. Both RCTs and observational studies demonstrated a comparable reduction in reoperation rate with TDT. These data in aggregate indicated that TDTs may not show superiority but emphasized differences between RCT and observational data.


  • Does pancreatic duct stent placement lead to decreased postoperative pancreatic fistula rates after pancreaticoduodenectomy? A meta-analysis

    by Chenchen Guo, Bin Xie, Diandian Guo

    To evaluate the effectiveness of pancreatic duct stent placement for preventing postoperative pancreatic fistula after pancreaticoduodenectomy. PubMed, the Cochrane Central Register of Controlled Trials, Embase and ClinicalTrials.gov databases were searched up to February 26, 2022. Studies comparing outcomes following pancreaticoduodenectomy with or without pancreatic duct stents were included. The primary outcome measured was postoperative pancreatic fistula rate, and secondary outcomes were in-hospital mortality rate, reoperation rate, delayed gastric emptying rate and wound infection rate. Seven RCTs involving 847 patients met the inclusion criteria. No statistically significant difference between the stent group and non-stent group was detected in the incidence of postoperative pancreatic fistula (RR = 0.85, 95%CI: 0.57-1.26, P = 0.41), in-hospital mortality, reoperation, delayed gastric emptying rate and wound infection. Subgroup analyses revealed that use of an external stent significantly reduced the incidence of pancreatic fistula (RR = 0.61, 95%CI: 0.43-0.86, P = 0.005). Our preliminary results from this systematic review and meta-analysis revealed that pancreatic duct stents did not reduce the risk of POPF and other complications after pancreaticoduodenectomy compared with no stents. External stents were associated with a reduced POPF rate compared with no stents. Large-scale RCTs are required to assess the effectiveness and assist in clarifying the real role of pancreatic duct stents with respect to the POPF rates after pancreaticoduodenectomy.


  • Prophylactic negative pressure wound therapy on surgical site infection in obese women after cesarean section: A systematic review and meta‐analysis

    by Chenchen Guo, Tao Cheng, Junsheng Li

    Background Prevention of surgical site infection (SSI) is a public health challenge. Objectives To evaluate the efficacy of negative pressure wound therapy (NPWT) for preventing SSI and other wound complications in obese women undergoing cesarean section. Search strategy The search terms included “negative pressure wound therapy”, “obesity” and “cesarean section/delivery”. Selection criteria Randomized controlled trials comparing the use of NPWT to standard dressings in preventing SSI in obese women after cesarean section. Data collection and analysis A comprehensive literature search of four databases was performed up to June, 2021. The primary outcome was SSI. Secondary outcomes were seroma, hematoma, overall wound complications and adverse skin reactions. Main results 10 RCTs involving 5586 patients met the inclusion criteria. The use of NPWT reduced SSI (RR=0.76, 95%CI: 0.63-0.92, P=0.004). No statistically significant difference was detected in the incidence of overall wound complications (RR = 0.93, P = 0.48), seroma (RR = 1.10, P=0.79), hematoma (RR = 0.63, P=0.36) and hospital readmission (RR = 1.41, P= 0.15). NPWT significantly increased the occurrence of skin blistering with a RR of 4.60 (P=0.04). Conclusions Use of prophylactic NPWT after cesarean delivery among obese women is associated with a significant reduction of surgical site infection.